AX-2026-041865 · ARA-290 · GSP lot GSP-2605-K3362

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 15 min gradient, 214 nm	99.59	% area	≥ 98.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.41	% area	≤ 2.0	PASS
Largest single impurity	RP-HPLC — des-Gln truncate (−128 Da)	0.27	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	93.00	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	92.62	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	1.92	mg	2 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	1.778	mg	2 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	88.9	%	90.0 – 110.0	FAIL
Water content	Karl Fischer, coulometric, duplicate	3.47	%	≤ 10.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	3.00	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.53	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Slow dissolution, >5 min to clarity	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.71	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 15 min gradient	4.60	min	4.71 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.28	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	67,019	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Ser]-diastereomer	0.82	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 15 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 67,019, and skew follows the reported asymmetry factor of 1.28. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.27 % impurity against a 99.59 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	ARA-290 — main peak	4.60	4,840,383	99.59	—
2	des-Gln truncate (−128 Da)	4.45	13,123	0.27	-128.059
3	deamidated (+1 Da)	4.49	3,888	0.08	+0.984
4	acetyl adduct (+42 Da)	4.80	1,944	0.04	+42.011
5	[D-Ser]-diastereomer	4.54	972	0.02	0.000
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	3.47
Counter-ion (acetate)	ion chromatography	3.00
Residual solvent + inorganic residue	estimated	0.53
Total peptide content	by difference	93.00
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.59	divergence +0.45 pp vs batch median
Total impurities (% area)	not stated	0.41
Largest single impurity (% area)	not stated	0.27
Water (%)	1.0	3.47
Counter-ion (%)	not stated	3.00
Peptide content (%w/w)	94.2	93.00
Endotoxin (EU/mg)	1.53	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Domestic warehouse despatch → submitter (2–8 °C, 30 d) → laboratory (courier, cold pack, 3 d) → assay.
Assay date: 01 May 2026
Submitted to the index: 20 May 2026
Laboratory: Kestrel Bioanalytical, Melbourne, Australia
Method basis: 15 min gradient · unit-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

retest_date20 May 2026

A retest date on the certificate would tell you what the supplier is actually asserting about stability. Purity at 99.59 % on assay day is a starting condition, not a shelf life.

lot_traceability20 May 2026

Lot GSP-2605-K3362 on the vial matches the certificate that came with it. That is the check every buyer can do in ten seconds and most do not.

sec_monomer20 May 2026

Where the close neighbour is an aggregate rather than a related substance, size exclusion separates them trivially and reverse phase never will.

Section 7

Related records

Same batch — lot GSP-2605-K3362 n=5

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-041862	GSP-2605-K3362	Janoshik	2026-Q2	99.34	3.32	—	Buyer-sourced	PASS
AX-2026-041863	GSP-2605-K3362	Janoshik	2026-Q2	99.36	3.11	—	Buyer-sourced	PASS
AX-2026-041864	GSP-2605-K3362	Nordanalyt	2026-Q2	99.92	3.06	—	Buyer-sourced	PASS
AX-2026-041866	GSP-2605-K3362	Janoshik	2026-Q2	99.45	2.95	91.1	Buyer-sourced	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent ARA-290 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-041767	ASY	ASY-{CAT}-1521	Janoshik	2026-Q3	99.66	4.42	103.7	Buyer-sourced	PASS
AX-2026-043222	SGN	SGN-2605-X9069	PeptideMeter	2026-Q2	98.32	7.36	—	Buyer-sourced	PASS
AX-2026-041907	SinoPep	SNP-2605-G4075	Janoshik	2026-Q2	99.20	5.75	—	Buyer-sourced	PASS
AX-2026-043227	SGN	SGN-2605-X9069	PeptideMeter	2026-Q2	98.38	7.21	95.6	Buyer-sourced	PASS
AX-2026-041862	GSP	GSP-2605-K3362	Janoshik	2026-Q2	99.34	3.32	—	Buyer-sourced	PASS
AX-2026-041906	SinoPep	SNP-2605-G4075	Medutest	2026-Q2	98.94	5.28	—	Buyer-sourced	PASS
AX-2026-042346	Homopeptide	HOMO-2601-T3123	PeptideMeter	2026-Q2	99.70	3.47	—	Buyer-sourced	PASS
AX-2026-043229	SGN	SGN-2605-X9069	Janoshik	2026-Q2	98.21	7.43	—	Buyer-sourced	PASS

Other recent GSP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041831	Survodutide	GSP-2603-E3156	Kestrel	2026-Q3	99.91	5.50	93.2	Buyer-sourced	0	PASS
AX-2026-041836	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.65	5.34	90.3	Buyer-sourced	0	PASS
AX-2026-041837	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.33	5.37	—	Buyer-sourced	0	PASS
AX-2026-041833	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.08	4.91	99.3	Buyer-sourced	0	PASS
AX-2026-041832	Survodutide	GSP-2603-E3156	VendorInvestigate	2026-Q3	98.01	5.14	99.5	Buyer-sourced	0	PASS
AX-2026-041835	Survodutide	GSP-2603-E3156	Nordanalyt	2026-Q3	98.34	5.74	89.0	Buyer-sourced	1	MARGINAL
AX-2026-041834	Survodutide	GSP-2603-E3156	VendorInvestigate	2026-Q3	97.92	5.95	—	Buyer-sourced	0	PASS
AX-2026-041838	Survodutide	GSP-2603-E3156	PeptideMeter	2026-Q3	98.30	5.01	102.4	Buyer-sourced	0	PASS